Drug Type Antibody fusion proteins |
Synonyms- |
Target |
Mechanism IL-2R modulators(Interleukin-2 receptor modulators), Interleukin-15 receptors antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis | Preclinical | CN | 12 Nov 2024 | |
Dermatitis, Atopic | Preclinical | CN | 12 Nov 2024 | |
Diabetes Mellitus, Type 1 | Preclinical | CN | 12 Nov 2024 | |
Lupus Vulgaris | Preclinical | CN | 12 Nov 2024 |